Who is sponsoring NCT06907641?

NCT06907641 is sponsored by St Vincent's Hospital, Sydney.

What drugs are being tested in NCT06907641?

Interventions in NCT06907641: 64Cu-SAR-bisPSMA.

What condition does NCT06907641 study?

NCT06907641 studies Prostate Cancer (Post Prostatectomy).

Is NCT06907641 still recruiting?

NCT06907641 is currently recruiting now. Last updated 1 April 2025.

Last reviewed 2025-04-01 · How we verify

NCT06907641: Co-PSMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

Recruiting now Phase 2 Last updated 1 April 2025

What this trial tests

Phase 2 trial testing 64Cu-SAR-bisPSMA in Prostate Cancer (Post Prostatectomy) in 50 participants. Currently enrolling.

Timeline

21 November 2024

Primary endpoint
1 November 2025

1 November 2025

Quick facts

Lead sponsor	St Vincent's Hospital, Sydney
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	21 November 2024
Primary completion	1 November 2025
Estimated completion	1 November 2025
Sites	1 location across Australia

Drugs / interventions tested

64Cu-SAR-bisPSMA — full drug profile →

Conditions studied

Prostate Cancer (Post Prostatectomy) — all drugs for Prostate Cancer (Post Prostatectomy) →

Sponsor

St Vincent's Hospital, Sydney

Who can join

18 and older, male only, with Prostate Cancer (Post Prostatectomy). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Detection rate of lesions per participants, between 64Cu-SAR-bisPSMA and 68Ga PSMA-11 PET/CT
Time frame: 12 months
Compare the detection rate of sites of prostate cancer recurrence, as determined by number of lesions per participants, between 64Cu-SAR-bisPSMA and 68Ga PSMA-11 PET/CT in patients with biochemical recurrence following radical prostatectomy who are being considered for curative salvage radiotherapy.

Sponsor's own description

The goal of this clinical trial is to compare 64Cu-SAR-bisPSMA PET/CT and 68Ga PSMA-11 PET/CT in men with biochemical failure following radical prostatectomy. The main questions it aims to answer are: * Is there a difference in the number of lesions of prostate cancer recurrence detected between the 64Cu-SAR-bisPSMA PET/CT and 68Ga PSMA-11 PET/CT scans. * What is the diagnostic accuracy of 64Cu-SAR-bisPSMA PET/CT compared to 68Ga PSMA-11 PET/CT using a standard of care comparator. * Evaluate the magnitude of clinical management change when using 64Cu-SAR-bisPSMA additional to standard of care imaging (68Ga PSMA-11). Participants will: * have 3 visits: 1) standard of care 68Ga PSMA-11 dose and PET/CT scan; 2) 64Cu-SAR-bisPSMA dose and PET/CT; 3) 64Cu-SAR-bisPSMA PET/CT only * have standard of care blood test either at Visit 1 or Visit 2

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
Khan S, Papa N, Kneebone A, Eade T, et al · · 2026 · cited 1× · PMID 41904043 · DOI 10.1016/j.eururo.2026.03.001
CopperNostics-Here We Are Now, Entertain Us!
Brühlmann SA, Walther M, Kopka K, Kreller M, et al · · 2026 · PMID 41754861 · DOI 10.3390/ph19020321
Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics.
Rodrigues D, Fonseca AI, Moreira JN, Gomes C, et al · · 2025 · PMID 41251982 · DOI 10.1186/s13550-025-01325-4

Verify or expand the search:

Other trials of 64Cu-SAR-bisPSMA

Trials testing the same drug.

NCT06970847 — 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate C · Phase 3 · recruiting
NCT05249127 — 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA) · Phase 1, PHASE2 · completed
NCT05286840 — 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer · Phase 1, PHASE2 · unknown
NCT04839367 — Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPEL · Phase 1 · completed

Other recruiting trials for Prostate Cancer (Post Prostatectomy)

Currently open trials in the same condition.

NCT07520916 — The Effect of Mobile-Based Perioperative Education on Urinary Incontinence and Erectile Function After Radical Prostatec · NA · recruiting
NCT07477626 — Radiotherapy After Prostatectomy for Node Positive Prostate Cancer · Phase 3 · active not recruiting
NCT07484971 — Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria · recruiting
NCT06687538 — Effect of Education to be Provided to Patients to Undergo TURP With Mobile Application on Patient Outcomes · NA · recruiting
NCT06850116 — Analysis of Immediate Urinary Continence Predictors After RS-RARP · active not recruiting

Other St Vincent's Hospital, Sydney trials

Trials by the same sponsor.

NCT07203391 — Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis · Phase 1 · recruiting
NCT05889728 — Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer · Phase 2 · unknown
NCT05613842 — Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP) · Phase 2 · completed
NCT05187884 — Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma · Phase 2 · active not recruiting
NCT04925648 — Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06907641 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St Vincent's Hospital, Sydney
Last refreshed: 1 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06907641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing